Biohaven Ltd. (BHVN)
10.78
-0.65
(-5.69%)
USD |
NYSE |
Oct 16, 16:00
10.79
+0.01
(+0.09%)
Pre-Market: 20:00
Biohaven Enterprise Value : 1.657B for Oct. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 16, 2026 | 1.657B |
| October 15, 2026 | 1.755B |
| October 14, 2026 | 1.680B |
| October 13, 2026 | 1.754B |
| October 12, 2026 | 1.813B |
| October 09, 2026 | 1.853B |
| October 08, 2026 | 1.831B |
| October 07, 2026 | 1.823B |
| October 06, 2026 | 1.853B |
| October 05, 2026 | 1.988B |
| October 02, 2026 | 1.973B |
| October 01, 2026 | 2.013B |
| September 30, 2026 | 2.045B |
| September 29, 2026 | 2.036B |
| September 28, 2026 | 2.033B |
| September 25, 2026 | 1.991B |
| September 24, 2026 | 2.021B |
| September 23, 2026 | 2.093B |
| September 22, 2026 | 2.272B |
| September 21, 2026 | 2.177B |
| September 18, 2026 | 2.086B |
| September 17, 2026 | 2.127B |
| September 16, 2026 | 1.844B |
| September 15, 2026 | 1.893B |
| September 14, 2026 | 1.938B |
| Date | Value |
|---|---|
| September 11, 2026 | 1.948B |
| September 10, 2026 | 1.961B |
| September 09, 2026 | 2.294B |
| September 08, 2026 | 2.252B |
| September 04, 2026 | 2.399B |
| September 03, 2026 | 2.424B |
| September 02, 2026 | 2.399B |
| September 01, 2026 | 2.406B |
| August 31, 2026 | 2.335B |
| August 28, 2026 | 2.356B |
| August 27, 2026 | 2.463B |
| August 26, 2026 | 2.589B |
| August 25, 2026 | 2.201B |
| August 24, 2026 | 2.095B |
| August 21, 2026 | 2.121B |
| August 20, 2026 | 2.068B |
| August 19, 2026 | 2.164B |
| August 18, 2026 | 2.078B |
| August 17, 2026 | 2.213B |
| August 14, 2026 | 2.240B |
| August 13, 2026 | 2.272B |
| August 12, 2026 | 2.202B |
| August 11, 2026 | 2.217B |
| August 10, 2026 | 2.225B |
| August 07, 2026 | 2.243B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| NovelStem International Corp. | 2.190M |
| Brainstorm Cell Therapeutics, Inc. | 9.949M |
| Summit Therapeutics, Inc. | 10.93B |
| Kezar Life Sciences, Inc. | -11.12M |
| Protara Therapeutics, Inc. | -2.670M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -137.31M |
| Total Expenses (Quarterly) | 137.31M |
| EPS Diluted (Quarterly) | -0.9115 |
| Earnings Yield | -43.10% |
| Normalized Earnings Yield | -42.60 |